Skip to main content
Klotho Neurosciences, Inc. logo

Klotho Neurosciences, Inc. — Investor Relations & Filings

Ticker · KLTO ISIN · US7580831094 US Manufacturing
Filings indexed 209 across all filing types
Latest filing 2026-05-26 Proxy Solicitation & In…
Country US United States of America
Listing US KLTO

About Klotho Neurosciences, Inc.

https://klothoneuro.com/

Klotho Neurosciences, Inc. is a biopharmaceutical company focused on the development of disease-modifying therapies for age-related cognitive and neurodegenerative disorders. The company develops treatments for conditions with high unmet medical needs, including amyotrophic lateral sclerosis (ALS), Alzheimer's, and Parkinson's disease. Its core approach involves pioneering gene and cell therapies that utilize DNA and RNA as therapeutics. A key area of its research is centered on genomic therapies targeting the alpha-Klotho gene, a known regulator of aging. The company's portfolio consists of proprietary cell and gene therapy programs designed to offer transformative outcomes for patients.

Recent filings

Filing Released Lang Actions
PROXY STATEMENT
Proxy Solicitation & Information Statement
2026-05-26 English
CURRENT REPORT
Regulatory Filings
2026-05-21 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2026
2026-05-20 English
AMENDMENT NO. 1 TO FORM 8-K
Regulatory Filings
2026-05-19 English
CURRENT REPORT
Regulatory Filings
2026-05-14 English
8-K - Greenland Mines Ltd (0001907223) (Filer)
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report under the Securities Exchange Act of 1934. The key content is the appointment of a new director to the Board of Directors, including detailed biographical information about the appointee. The document is dated April 17, 2026, and includes the signature of the CEO. The main item reported is Item 5.02, which relates to the departure or appointment of directors or certain officers. There are no financial statements or earnings data, no audit information, no voting results, no merger or acquisition details, and no other report types mentioned. Therefore, this filing is best classified as Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document length (5899 characters) supports it being a full report rather than a brief announcement or certification. Confidence is high due to the clear and specific content about board appointment.
2026-04-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.